肺癌早期篩查和診斷的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

BI Lingfeng ^1,2,3 , WANG Xin ^1,2,3 , LUO Wenxin ^1,2,3 , LIU Dan ^1,2,3,4,5 , LI Weimin ^1,2,3,4,5 ,  WANG Zhoufeng ^1,2,3

1. ;
2. ;
3. ;
4. ;
5. ;

Corresponding?author：

WANG Zhoufeng, Email: wangzhoufeng@wchscu.edu.cn

Keywords：

DOI：

10.7507/1671-6205.202502085

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： BI Lingfeng, WANG Xin, LUO Wenxin, LIU Dan, LI Weimin, WANG Zhoufeng. 肺癌早期篩查和診斷的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2025, 24(8): 583-590. doi: 10.7507/1671-6205.202502085 Copy

1.	雷弋, 陳勃江, 曾莉, 等. 低劑量計算機斷層成像在高危人群早期肺癌篩查中的價值研究. 四川大學學報(醫學版), 2012, 43(4): 584-587.
2.	Kim EE, Cenzer I, Graham FJ, et al. Time to benefit for lung cancer screening: a systematic review and survival meta-analysis. Am J Prev Med, 2025, 69(2): 107736.
3.	石俊英, 王慧, 張斯佳, 等. LDCT、腫瘤相關自身抗體、TFPI-2基因甲基化聯合檢測對肺癌的早期診斷價值. 實用癌癥雜志, 2023, 38(10): 1634-1637+1653.
4.	Ji G, Bao T, Li Z, et al. Current lung cancer screening guidelines may miss high-risk population: a real-world study. BMC cancer, 2021, 21: 1-10.
5.	Pinzani P, D’Argenio V, Del Re M, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med, 2021, 59(7): 1181-1200.
6.	Yousefi M, Ghaffari P, Nosrati R, et al. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer, Cell Oncol (Dordr), 2020, 43(1): 31-49.
7.	Chang JW, Shih CL, Wang CL, et al, Transcriptomic analysis in liquid biopsy identifies circulating PCTAIRE-1 mRNA as a biomarker in NSCLC, Cancer Genomics Proteomics, 2020, 17(1): 91-100,.
8.	Dong S, Wang Z, Zhang JT, et al, Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial, JAMA Oncol, 2024;10(7): 932-940,.
9.	Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2023;12(3): 615-628.
10.	Cortés-Hernández LE, Eslami-S Z, Attina A, et al. Proteomic profiling and functional analysis of extracellular vesicles from metastasis-competent circulating tumor cells in colon cancer. J Exp Clin Cancer Res. 2025;44(1): 102.
11.	Alix-Panabières C, Pantel K. Advances in liquid biopsy: from exploration to practical application. Cancer Cell. 2025;43(2): 161-165.
12.	Pang LL, Zhuang WT, Chen ZH, et al. Chemotherapy-based combination regimens for advanced EGFR-mutant NSCLC after EGFR-TKI failure: a network meta-analysis. J Natl Compr Canc Netw. 2025;23(4): e247092.
13.	Zhang X, Yang D, Jiang Y, Huang L, Wang C, Tao D, et al. Comparison of radiation pneumonitis in lung Cancer patients treated with HT versus IMRT and circulating lymphocyte subsets as predicting risk factors. J Inflamm Res. 2021;14: 4205–4215.
14.	Zhang B, Niu X, Zhang Q , et al. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-smallcell lung cancer. Lung Cancer, 2019, 134: 108-116.
15.	Zong Y, Li Q, Zhang F, et al. SDH5 depletion enhances radiosensitivity by regulating p53: a new method for noninvasive prediction of radiotherapy response. Theranostics, 2019, 9(22): 6380-6395.
16.	Lee S, You J, Baek I, et al. Synergistic enhanced rolling circle amplification based on mutS and radical polymerization for single-point mutation DNA detection. Biosens Bioelectron, 2022, 210: 114295.
17.	Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 2019, 566(7745): 553-557.
18.	Sun J, Lu Z, Fu W, Lu K, Gu X, Xu F, et al. Exosome-derived ADAM17 promotes liver metastasis in colorectal Cancer. Front Pharmacol, 2021, 12: 734351.
19.	Labani-Motlagh A, Naseri S, Wenthe J, et al. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther Oncolytics, 2021, 20: 508-18.
20.	Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancerassociated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer, 2021, 20(1): 131.
21.	Medina JE, Annapragada AV, Lof P, et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discov, 2025, 15(1): 105-118.
22.	Bruhm DC, Vulpescu NA, Foda ZH, et al. Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection. Nat Rev Cancer, 2025, 25(5): 341-358.
23.	Jiang C, Zhang N, Hu X, Wang H. Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer, 2021, 20(1): 117.
24.	Tian Y, Xu L, Li X, et al. SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Lett, 2023, 554: 216022.
25.	Heeke S, Gay CM, Estecio MR, et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell, 2024;42(2): 225-237. e5.
26.	Lau SCM, Pan Y, Velcheti V, et al. Squamous cell lung cancer: current landscape and future therapeutic options. Cancer Cell, 2022, 40(11): 1279-1293.
27.	Waarts MR, Stonestrom AJ, Park YC, et al. Targeting mutations in cancer. J Clin Invest, 2022, 132(8): e154943.
28.	Yang M, Yu H, Feng H, et al. Enhancing the differential diagnosis of small pulmonary nodules: a comprehensive model integrating plasma methylation, protein biomarkers, and LDCT imaging features. J Transl Med, 2024, 22(1): 984.
29.	Bhalla S, Yi S, Gerber DE. Emerging strategies in lung cancer screening: blood and beyond. Clin Chem, 2024, 70(1): 60-67.
30.	Dai J, Qu T, Yin D, et al. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer. Cell Death Dis, 2023, 14(5): 312.
31.	Chennamadhavuni A, Abushahin L, Jin N, et al. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol, 2022, 13: 779691.
32.	Les I, Martínez M, Pérez-Francisco I, et al. Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel), 2023, 15(5): 1629.
33.	Zhao Y, O'Keefe CM, Hsieh K, et al. Multiplex digital methylation-specific PCR for noninvasive screening of lung cancer. Adv Sci (Weinh), 2023, 10(16): e2206518.
34.	Yang Q, Wang M, Xu J, et al. LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling. Mol Cancer, 2023, 22(1): 122.
35.	Pei H, Dai Y, Yu Y, et al. The tumorigenic effect of lncRNA AFAP1-AS1 is mediated by translated peptide ATMLP under the control of m6A methylation. Adv Sci (Weinh), 2023, 10(13): e2300314.
36.	羅汶鑫, 李為民. 肺癌的表觀遺傳學研究進展及其臨床意義. 中國呼吸與危重監護雜志, 2018, 17(03): 313-318.
37.	Long Y, Wang C, Wang T, et al. High performance exhaled breath biomarkers for diagnosis of lung cancer and potential biomarkers for classification of lung cancer. J Breath Res, 2021, 15(1): 016017.
38.	陳情, 孫美秀, 李靜, 等. 肺癌早診呼吸分析研究現狀與臨床應用前景. 國際呼吸雜志, 2019, 39: 1800-1804.
39.	謝少華, 向潤, 謝天鵬等. 呼出氣分析與肺癌診斷的研究現狀及進展. 中國胸心血管外科臨床雜志, 2022, 29(9): 1197-1209.
40.	Yuan J, Zhou F, Guo Z, et al. HCformer: Hybrid CNN-Transformer for LDCT Image Denoising. J Digit Imaging, 2023, 36: 2290-2305.
41.	Fonti R, Conson M, Del Vecchio S. PET/CT in radiation oncology. Semin Oncol, 2019, 46: 202-209.
42.	Paydary K, Seraj SM, Zadeh MZ, et al. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol, 2019, 21: 1-10.
43.	Owens C, Hindocha S, Lee R, et al. The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives. Br J Radiol, 2023, 96: 20220339.
44.	Allen BD, Schiebler ML, Sommer G, et al. Cost-effectiveness of lung MRI in lung cancer screening. Eur Radiol, 2020, 30: 1738-1746.
45.	張新宇, 江崢增, 李春, 等. 支氣管沖洗液輔助現場快速評估為陰性的肺癌進行表皮生長因子受體基因檢測的臨床應用價值. 中華病理學雜志, 2018, 47(12): 915-918.
46.	李為民;趙爽;劉倫旭. 肺癌早期診斷方法及臨床意義. 四川大學學報(醫學版), 2017, 48(03): 331-335+326.
47.	Vincent BD, Fraig M, Silvestri GA. A pilot study of narrow-band imaging compared to white light bronchoscopy for evaluation of normal airways and premalignant and malignant airways disease. Chest, 2007, 131(6): 1794-1799.
48.	Iftikhar IH, Musani AI. Narrow-band imaging bronchoscopy in the detection of premalignant airway lesions: a meta-analysis of diagnostic test accuracy. Therapeutic advances in respiratory disease, 2015, 9(5): 207-216.
49.	陳海;張仁泉. 電磁導航支氣管鏡在肺結節診斷及治療中的應用研究進展. 安徽醫學, 2023, 44(09): 1141-1143.
50.	李鐳;劉丹;張立;周萍;宋娟;程越;余何;趙爽;李為民. 6458例肺癌患者臨床特征及診療現狀分析. 四川大學學報(醫學版), 2017, 48(03): 352-358.
51.	Poletti V, Poletti G, Murer B, et al. Bronchoalveolar lavage in malignancy[C]//Seminars in Respiratory and Critical Care Medicine. Thieme Medical Publishers, 2007, 28(5): 534-545.
52.	余何;李鐳;劉丹;李為民. TTF-1、NapsinA、P63和CK5/6在肺癌組織的表達與分型診斷的價值. 四川大學學報(醫學版), 2017, 48(3): 336-341.
53.	人工智能在肺結節診治中的應用專家共識(2022年版). 中國肺癌雜志, 2022, 25(4): 219-225.
54.	Halder A, Dey D, Sadhu AK. Lung nodule detection from feature engineering to deep learning in thoracic CT images: a comprehensive review. J Digit Imaging, 2020, 33(3): 655677.
55.	Mao Y, Xu N, Wu Y, et al. Assessments of lung nodules by an artificial intelligence chatbot using longitudinal CT images. Cell Rep Med, 2025, 6(3): 101988.
56.	Deng Y, Yao Y, Wang Y, et al. An end-to-end deep learning method for mass spectrometry data analysis to reveal disease-specific metabolic profiles. Nat Commun, 2024, 15(1): 7136.
57.	de Margerie-Mellon C, Chassagnon G. Artificial intelligence: a critical review of applications for lung nodule and lung cancer. Diagn Interv Imaging. 2023;104(1): 11-17.
58.	Quanyang W, Yao H, Sicong W, et al. Artificial intelligence in lung cancer screening: detection, classification, prediction, and prognosis. Cancer Med, 2024, 13(7): e7140.

1. 雷弋, 陳勃江, 曾莉, 等. 低劑量計算機斷層成像在高危人群早期肺癌篩查中的價值研究. 四川大學學報(醫學版), 2012, 43(4): 584-587.
2. Kim EE, Cenzer I, Graham FJ, et al. Time to benefit for lung cancer screening: a systematic review and survival meta-analysis. Am J Prev Med, 2025, 69(2): 107736.
3. 石俊英, 王慧, 張斯佳, 等. LDCT、腫瘤相關自身抗體、TFPI-2基因甲基化聯合檢測對肺癌的早期診斷價值. 實用癌癥雜志, 2023, 38(10): 1634-1637+1653.
4. Ji G, Bao T, Li Z, et al. Current lung cancer screening guidelines may miss high-risk population: a real-world study. BMC cancer, 2021, 21: 1-10.
5. Pinzani P, D’Argenio V, Del Re M, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med, 2021, 59(7): 1181-1200.
6. Yousefi M, Ghaffari P, Nosrati R, et al. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer, Cell Oncol (Dordr), 2020, 43(1): 31-49.
7. Chang JW, Shih CL, Wang CL, et al, Transcriptomic analysis in liquid biopsy identifies circulating PCTAIRE-1 mRNA as a biomarker in NSCLC, Cancer Genomics Proteomics, 2020, 17(1): 91-100,.
8. Dong S, Wang Z, Zhang JT, et al, Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial, JAMA Oncol, 2024;10(7): 932-940,.
9. Desai A, Lovly CM. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2023;12(3): 615-628.
10. Cortés-Hernández LE, Eslami-S Z, Attina A, et al. Proteomic profiling and functional analysis of extracellular vesicles from metastasis-competent circulating tumor cells in colon cancer. J Exp Clin Cancer Res. 2025;44(1): 102.
11. Alix-Panabières C, Pantel K. Advances in liquid biopsy: from exploration to practical application. Cancer Cell. 2025;43(2): 161-165.
12. Pang LL, Zhuang WT, Chen ZH, et al. Chemotherapy-based combination regimens for advanced EGFR-mutant NSCLC after EGFR-TKI failure: a network meta-analysis. J Natl Compr Canc Netw. 2025;23(4): e247092.
13. Zhang X, Yang D, Jiang Y, Huang L, Wang C, Tao D, et al. Comparison of radiation pneumonitis in lung Cancer patients treated with HT versus IMRT and circulating lymphocyte subsets as predicting risk factors. J Inflamm Res. 2021;14: 4205–4215.
14. Zhang B, Niu X, Zhang Q , et al. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-smallcell lung cancer. Lung Cancer, 2019, 134: 108-116.
15. Zong Y, Li Q, Zhang F, et al. SDH5 depletion enhances radiosensitivity by regulating p53: a new method for noninvasive prediction of radiotherapy response. Theranostics, 2019, 9(22): 6380-6395.
16. Lee S, You J, Baek I, et al. Synergistic enhanced rolling circle amplification based on mutS and radical polymerization for single-point mutation DNA detection. Biosens Bioelectron, 2022, 210: 114295.
17. Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 2019, 566(7745): 553-557.
18. Sun J, Lu Z, Fu W, Lu K, Gu X, Xu F, et al. Exosome-derived ADAM17 promotes liver metastasis in colorectal Cancer. Front Pharmacol, 2021, 12: 734351.
19. Labani-Motlagh A, Naseri S, Wenthe J, et al. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther Oncolytics, 2021, 20: 508-18.
20. Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancerassociated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer, 2021, 20(1): 131.
21. Medina JE, Annapragada AV, Lof P, et al. Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers. Cancer Discov, 2025, 15(1): 105-118.
22. Bruhm DC, Vulpescu NA, Foda ZH, et al. Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection. Nat Rev Cancer, 2025, 25(5): 341-358.
23. Jiang C, Zhang N, Hu X, Wang H. Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms. Mol Cancer, 2021, 20(1): 117.
24. Tian Y, Xu L, Li X, et al. SMARCA4: current status and future perspectives in non-small-cell lung cancer. Cancer Lett, 2023, 554: 216022.
25. Heeke S, Gay CM, Estecio MR, et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell, 2024;42(2): 225-237. e5.
26. Lau SCM, Pan Y, Velcheti V, et al. Squamous cell lung cancer: current landscape and future therapeutic options. Cancer Cell, 2022, 40(11): 1279-1293.
27. Waarts MR, Stonestrom AJ, Park YC, et al. Targeting mutations in cancer. J Clin Invest, 2022, 132(8): e154943.
28. Yang M, Yu H, Feng H, et al. Enhancing the differential diagnosis of small pulmonary nodules: a comprehensive model integrating plasma methylation, protein biomarkers, and LDCT imaging features. J Transl Med, 2024, 22(1): 984.
29. Bhalla S, Yi S, Gerber DE. Emerging strategies in lung cancer screening: blood and beyond. Clin Chem, 2024, 70(1): 60-67.
30. Dai J, Qu T, Yin D, et al. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer. Cell Death Dis, 2023, 14(5): 312.
31. Chennamadhavuni A, Abushahin L, Jin N, et al. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol, 2022, 13: 779691.
32. Les I, Martínez M, Pérez-Francisco I, et al. Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel), 2023, 15(5): 1629.
33. Zhao Y, O'Keefe CM, Hsieh K, et al. Multiplex digital methylation-specific PCR for noninvasive screening of lung cancer. Adv Sci (Weinh), 2023, 10(16): e2206518.
34. Yang Q, Wang M, Xu J, et al. LINC02159 promotes non-small cell lung cancer progression via ALYREF/YAP1 signaling. Mol Cancer, 2023, 22(1): 122.
35. Pei H, Dai Y, Yu Y, et al. The tumorigenic effect of lncRNA AFAP1-AS1 is mediated by translated peptide ATMLP under the control of m6A methylation. Adv Sci (Weinh), 2023, 10(13): e2300314.
36. 羅汶鑫, 李為民. 肺癌的表觀遺傳學研究進展及其臨床意義. 中國呼吸與危重監護雜志, 2018, 17(03): 313-318.
37. Long Y, Wang C, Wang T, et al. High performance exhaled breath biomarkers for diagnosis of lung cancer and potential biomarkers for classification of lung cancer. J Breath Res, 2021, 15(1): 016017.
38. 陳情, 孫美秀, 李靜, 等. 肺癌早診呼吸分析研究現狀與臨床應用前景. 國際呼吸雜志, 2019, 39: 1800-1804.
39. 謝少華, 向潤, 謝天鵬等. 呼出氣分析與肺癌診斷的研究現狀及進展. 中國胸心血管外科臨床雜志, 2022, 29(9): 1197-1209.
40. Yuan J, Zhou F, Guo Z, et al. HCformer: Hybrid CNN-Transformer for LDCT Image Denoising. J Digit Imaging, 2023, 36: 2290-2305.
41. Fonti R, Conson M, Del Vecchio S. PET/CT in radiation oncology. Semin Oncol, 2019, 46: 202-209.
42. Paydary K, Seraj SM, Zadeh MZ, et al. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol Imaging Biol, 2019, 21: 1-10.
43. Owens C, Hindocha S, Lee R, et al. The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives. Br J Radiol, 2023, 96: 20220339.
44. Allen BD, Schiebler ML, Sommer G, et al. Cost-effectiveness of lung MRI in lung cancer screening. Eur Radiol, 2020, 30: 1738-1746.
45. 張新宇, 江崢增, 李春, 等. 支氣管沖洗液輔助現場快速評估為陰性的肺癌進行表皮生長因子受體基因檢測的臨床應用價值. 中華病理學雜志, 2018, 47(12): 915-918.
46. 李為民;趙爽;劉倫旭. 肺癌早期診斷方法及臨床意義. 四川大學學報(醫學版), 2017, 48(03): 331-335+326.
47. Vincent BD, Fraig M, Silvestri GA. A pilot study of narrow-band imaging compared to white light bronchoscopy for evaluation of normal airways and premalignant and malignant airways disease. Chest, 2007, 131(6): 1794-1799.
48. Iftikhar IH, Musani AI. Narrow-band imaging bronchoscopy in the detection of premalignant airway lesions: a meta-analysis of diagnostic test accuracy. Therapeutic advances in respiratory disease, 2015, 9(5): 207-216.
49. 陳海;張仁泉. 電磁導航支氣管鏡在肺結節診斷及治療中的應用研究進展. 安徽醫學, 2023, 44(09): 1141-1143.
50. 李鐳;劉丹;張立;周萍;宋娟;程越;余何;趙爽;李為民. 6458例肺癌患者臨床特征及診療現狀分析. 四川大學學報(醫學版), 2017, 48(03): 352-358.
51. Poletti V, Poletti G, Murer B, et al. Bronchoalveolar lavage in malignancy[C]//Seminars in Respiratory and Critical Care Medicine. Thieme Medical Publishers, 2007, 28(5): 534-545.
52. 余何;李鐳;劉丹;李為民. TTF-1、NapsinA、P63和CK5/6在肺癌組織的表達與分型診斷的價值. 四川大學學報(醫學版), 2017, 48(3): 336-341.
53. 人工智能在肺結節診治中的應用專家共識(2022年版). 中國肺癌雜志, 2022, 25(4): 219-225.
54. Halder A, Dey D, Sadhu AK. Lung nodule detection from feature engineering to deep learning in thoracic CT images: a comprehensive review. J Digit Imaging, 2020, 33(3): 655677.
55. Mao Y, Xu N, Wu Y, et al. Assessments of lung nodules by an artificial intelligence chatbot using longitudinal CT images. Cell Rep Med, 2025, 6(3): 101988.
56. Deng Y, Yao Y, Wang Y, et al. An end-to-end deep learning method for mass spectrometry data analysis to reveal disease-specific metabolic profiles. Nat Commun, 2024, 15(1): 7136.
57. de Margerie-Mellon C, Chassagnon G. Artificial intelligence: a critical review of applications for lung nodule and lung cancer. Diagn Interv Imaging. 2023;104(1): 11-17.
58. Quanyang W, Yao H, Sicong W, et al. Artificial intelligence in lung cancer screening: detection, classification, prediction, and prognosis. Cancer Med, 2024, 13(7): e7140.

Previous Article
慢性嗜酸性粒細胞性肺炎四例報道并文獻復習
Next Article
老年社區獲得性肺炎治療及預防研究進展

Chinese Journal of Respiratory and Critical Care Medicine

肺癌早期篩查和診斷的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content